What is Zacks Research’s Estimate for BMRN Q3 Earnings?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Zacks Research raised their Q3 2025 EPS estimates for shares of BioMarin Pharmaceutical in a report released on Monday, February 17th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $0.73 per share for the quarter, up from their prior forecast of $0.72. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.71 EPS, Q2 2026 earnings at $0.86 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.97 EPS and FY2026 earnings at $3.52 EPS.

BMRN has been the subject of a number of other research reports. William Blair downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Citigroup upped their price objective on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a “neutral” rating in a research report on Thursday. Piper Sandler upped their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an “overweight” rating in a research report on Thursday. Bank of America upped their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wedbush reiterated an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.81.

BioMarin Pharmaceutical Stock Up 4.8 %

Shares of BioMarin Pharmaceutical stock opened at $68.73 on Thursday. The company has a market cap of $13.10 billion, a P/E ratio of 41.16, a PEG ratio of 0.57 and a beta of 0.28. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The firm has a fifty day moving average of $64.79 and a two-hundred day moving average of $71.06.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million during the quarter, compared to analysts’ expectations of $711.05 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds have recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $28,000. LRI Investments LLC boosted its stake in shares of BioMarin Pharmaceutical by 856.9% during the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 437 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in shares of BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 186 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth about $36,000. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of BioMarin Pharmaceutical by 64.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 233 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.